Division of Hematology and Medical Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA.
Clin Med Insights Oncol. 2011;5:163-9. doi: 10.4137/CMO.S6566. Epub 2011 May 24.
Castration resistant prostate cancer has historically been considered chemotherapy insensitive. However, the approval of estramustine phosphate, mitoxantrone, and docetaxel, over the past few decades, has challenged this notion. Despite these advances, until recently, only docetaxel had been shown to improve survival in patients with castration-resistant disease, and there has been no standard treatment options available for men with disease progression on docetaxel. In the last year, cabazitaxel, a novel taxane with decreased affinity for ATP-dependent drug efflux pump P-glycoprotein, became the first cytotoxic agent to demonstrate an improvement in survival in men with docetaxel-refractory disease, and has received regulatory approval for treatment in this setting. In this review, we examine the clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer, as well as rationale and direction of future therapeutic investigation.
去势抵抗性前列腺癌在历史上被认为对化疗不敏感。然而，在过去几十年中，依托泊苷磷酸盐、米托蒽醌和多西他赛的批准，对这一观念提出了挑战。尽管取得了这些进展，但直到最近，只有多西他赛显示出能改善去势抵抗性疾病患者的生存，而且对于多西他赛治疗后疾病进展的患者，仍然没有标准的治疗选择。在过去的一年中，卡巴他赛（一种新型紫杉烷类药物，对 ATP 依赖性药物外排泵 P-糖蛋白的亲和力降低）成为首个显示在多西他赛难治性疾病患者中生存改善的细胞毒性药物，并已获得该适应证的监管批准。在这篇综述中，我们探讨了卡巴他赛治疗去势抵抗性前列腺癌的临床开发，以及未来治疗研究的原理和方向。
